摘要： 脓毒症是临床常见的危重病之一,近年来由于抗生素、激素及免疫抑制剂的广泛应用,脓毒症的发病率和病死率持续升高。脓毒症早期即可诱发肝损伤,其发病机制不明,本文将近年来脓毒症肝损伤的发病机制及潜在治疗方向的进展做一阐述。
周伟, 章莉莉. 脓毒症肝损伤的发病机制及治疗研究进展[J]. 肝脏, 2023, 28(6): 734-737.
| [1] Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock(sepsis-3). JAMA, 2016, 315(8): 801-810. [2] Yao RQ, Ren C, Wang JN, et al. Publication trends of research on sepsis and host immune response during 1999-2019: A 20-year bibliometric analysis. Int J Biol Sci, 2020, 16(1) : 27-37. [3] Jenniskens M, Langouche L, Vanwijngaerden YM, et al. Cholestatic liver (dys)function during sepsis and other critical illnesses. Intensive Care Med, 2016, 42(1) : 16-27. [4] Huang M, Cai SL, Su JX. The pathogenesis of sepsis and potential therapeutic targets. Int J Mol Sci, 2019, 20(21) : 5376-5376. [5] Fiusa MM, Carvalho-Filho MA, Annichino-Bizzacchi JM, et al. Causes and consequences of coagulation activation in sepsis: an evolutionary medicine perspective. BMC Med, 2015, 13(1) : 105-105. [6] Sessler CN, Windsor AC, Schwartz M, et al. Circulating ICAM-1 is increased in septic shock. Am J Respir Crit Care Med, 1995, 151(5) : 1420-1427. [7] Zhang SJ, Han LL, Wan XY. Characteristics of sepsis-induced liver injury. Natl Med J China, 2017, 97(23): 1828-1830. [8] Rivers EP, Kruse JA, Jacobsen G, et al. The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock. Crit Care Med, 2007, 35(9): 2016-2024. [9] Ji Y, Yin Y, Li Z,et al.Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease (nafld). Nutrients, 2019, 11(8): 1712-1712. [10] Zhang X, Liu H, Hashimoto K,et al. The gut–liver axis in sepsis: interaction mechanisms and therapeutic potential. Crit Care, 2022, 26(1) : 213-213. [11] Gong S, Yan Z, Liu Z,et al. Intestinal microbiota mediates the susceptibility to polymicrobial sepsis-induced liver injury by granisetron generation in mice. Hepatology, 2019, 69(4) : 1751-1767. [12] 张杰,李小悦,黄家华,等.脓毒症相关肝损伤与肠-肝轴研究进展.实用医学杂志,2022,38(07):795-798. [13] Beringer A, Miossec P. IL-17 and TNF-alpha co-operation contributes to the proinflammatory response of hepatic stellate cells. Clin Exp Immunol, 2019, 198(1): 111-120. [14] Harbrecht BG, Di Silvio M, Demetris AJ, et al. Tumor necrosis factor-alpha regulates in vivo nitric oxide synthesis and induces liver injury during endotoxemia. Hepatology (Baltimore, Md.), 1994, 20(4 Pt 1) : 1055-1060. [15] 田涛,李幼生.脓毒症相关肝损害研究进展.中华危重症医学杂志(电子版), 2021, 14(02): 165-167. [16] Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation ofnaive CD4+ T cells. Immunity, 2002, 16(6): 779-790. [17] 李晗,陈强,韩旭东. 肝脏在脓毒症发生发展中的作用及机制. 交通医学,2020,34(1):11-14. [18] Sun J, Zhang J, Wang X, et al. Gut-liver crosstalk in sepsis induced liver injury. Crit Care, 2020, 24(1): 614-614. [19] Lv M, Wang C, Li F, et al. Structural insights into the recognition of phosphorylated FUNDC1 by LC3B in mitophagy. Protein Cell, 2017, 8(1): 25-38. [20] 石春霞, 王瑶, 陈倩, 等. 细胞外组蛋白在肝损伤炎症过程中的作用进展.中华肝脏病杂志, 2021, 29(11): 1124-1127. [21] Cogger VC, Mross PE, Hosie MJ, et al. The effect of acute oxidative stress on the ultrastructure of the perfused rat liver. Pharmacol Toxicol, 2001, 89(6): 306-311. [22] 江勉君, 史忠亮, 毛凯凤,等. 氧化应激在脓毒症中的发病机制. 医学综述, 2020, 26(5): 856-860. [23] Xing W, Yang L, Peng Y, et al. Ginsenoside Rg3 attenuates sepsisinduced injury and mitochondrial dysfunction in liver via AMPKmediated autophagy flux. Biosci Rep, 2017, 37(4): BSR20170934. [24] 管建慧, 易钊泉. 脓毒症肝损伤的致病机制及治疗新进展. 中国急救医学, 2019, 39(6): 601-604 [25] 王秋卉, 王锦权, 叶文, 等. 脓毒症对肝脏线粒体膜损伤机制的实验研究.中国急救医学, 2008, 28(2): 147-150. [26] Lorente L, Martín MM, Abreu-González P, et al. Prognostic value of malondialdehyde serum levels in severe sepsis: a multicenter study. PLoS One, 2013, 8(1): e53741. [27] Yang X, Lu GP, Cai XD, et al. Alterations of complex IV in the tissues of a septic mouse model. Mitochondrion, 2019, 49(C) : 89-96. [28] Vanhorebeek I, Gunst J, Derde S, et al. Mitochondrial fusion, fission, and biogenesis in prolonged criticalkly ill patients. J Clin Endocrinol Metab, 2012, 97(1): E59-E64. [29] Snyder AG, Oberst A. The Antisocial Network: Cross talk between cell death programs in host defense. Annu Rev Immunol, 2021, 39 : 77-101. [30] Brenner C, Galluzzi L, Kepp O, et al. Decoding cell death signals in liver inflammation. J Hepatol, 2013, 59(3) : 583-594. [31] Allaire M, Rauton PE, Codogno P, et al. Autophagy in liver diseases: time for translation? J Hepatol,2019,70(5): 985-998. [32] Wang F, Lei X, Zhao Y, et al. Protective role of thymoquinone in sepsis-induced liver injury in BALB/c mice. Exp Ther Med,2019,18(3):1985-1992. [33] Wen R, Liu YP, Tong XX,et al. Molecular mechanisms and functions of pyroptosis in sepsis and sepsis-associated organ dysfunction. Front Cell Infect Microbiol, 2022, 12 : 962139-962139. [34] Man SM, Karki R, Kanneganti TD.Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol Rev, 2017, 277(1) : 61-75. [35] Yang W, Tao K, Zhang P, et al. Maresin 1 protects against lipopolysaccharide/ d-galactosamine-induced acute liver injury by inhibiting macrophage pyroptosis and inflammatory response. Biochem Pharmacol, 2021, 195 : 114863-114863. [36] Wang J, Zhu Q, Li R, et al. YAP1 protects against septic liver injury via ferroptosis resistance. Cell Biosci, 2022, 12(1) : 163-163. [37] 曹钰,柴艳芬,邓颖,等.中国脓毒症/脓毒性休克急诊治疗指南(2018).感染、炎症、修复, 2019, 20(01): 3-22. [38] Taylor BE, McClave SA, Martindale RG, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine(SCCM) and American Society for Parenteral and Enteral Nutrition(ASPEN) . Crit Care Med, 2016, 44(2): 390-438. [39] Zeng QY, Zhang CM, Qian XH. Protective effects of continue insulin infusion on liver mitochondrion in the early stage of septic rats. Chin J Cell Mol Immunol, 2009, 25(6): 525-528. [40] Wang XJ, Zheng CH, Lv Q. Effect of alprostadil on inflammatory response and liver function in patients with acute liver injury induced by sepsis. Chin J Modern Med, 2018, 20(3): 71-73. [41] Ding R, Han J, Zhao D, et al. Pretreatment with Rho-kinase inhibitor ameliorates lethal endotoxemia-induced liver injury by improving mitochondrial function. Int Immunopharmacol, 2016, 40: 125-130. [42] Mainali R, Zabalawi M, Long D, et al. Dichloroacetate reverses sepsis-induced hepatic metabolic dysfunction. Elife, 2021, 10: e64611-e64611. [43] Hu K, Xiao L, Li L,et al. The mitochondria-targeting antioxidant MitoQ alleviated Lipopolysaccharide/ D-galactosamine-induced acute liver injury in mice. Immunol Lett, 2021, 240 : 24-30. [44] Xu S, Xu J, Hao T, et al. Paeonol alleviates lipopolysaccharide-induced hepatocytes injury through alteration of mitochondrial function and NF-kappa B translocation. Mol Med Rep, 2021, 24(5): 779. [45] Wei S, Bi J, Yang L, et al. Serum irisin levels are decreased in patients with sepsis, and exogenous irisin suppresses ferroptosis in the liver of septic mice. Clin Transl Med, 2020, 10(5): e173- e173. [46] Yan M, Yu Y, Mao X,et al. Hydrogen gas inhalation attenuates sepsis-induced liver injury in a FUNDC1-dependent manner. Int Immunopharmacol, 2019, 71 : 61-67. [47] 邢博民,郭娜,宁海慧,等.脓毒症肝损伤与自噬.中国肝脏病杂志(电子版),2021,13(03):37-41. [48] Thiessen SE, Derese I, Derde S, et al. The role of autophagy in critical illness-induced liver damage. Sci Rep, 2017, 7(1) : 14150-14150. |
| [1] | 孟尧, 张萌萌, 赵新颜. 药物性肝损伤因果关系评估演变:从RUCAM到RECAM[J]. 肝脏, 2023, 28(6): 631-633. |
| [2] | 曾伟兰, 汪艳. 内质网应激与非酒精性脂肪性肝病肝损伤[J]. 肝脏, 2023, 28(6): 633-636. |
| [3] | 陶子文, 杨长青. 肝硬化肌少症的治疗策略及研究方向[J]. 肝脏, 2023, 28(6): 643-645. |
| [4] | 郭丹丹, 覃岭, 高文峰, 袁春旺, 张英华, 张永宏. 血浆白介素33水平与原发性肝癌及热消融治疗的相关性分析[J]. 肝脏, 2023, 28(6): 665-667. |
| [5] | 王涵, 彭瑾, 金慧茹, 王潇, 戴晶晶, 李军, 蒋龙凤. 肺癌患者免疫治疗所致肝损伤的影响因素[J]. 肝脏, 2023, 28(6): 688-693. |
| [6] | 钱祥云, 黄大兵, 王峰. 免疫检查点抑制剂诱发肿瘤患者免疫介导性肝损伤的临床分析[J]. 肝脏, 2023, 28(6): 694-697. |
| [7] | 吴亚岭, 姚敏, 秦澄. 32例药物性肝损伤肝衰竭患者影响因素分析及预后评价[J]. 肝脏, 2023, 28(6): 698-701. |
| [8] | 叶圣莹, 秦燕. 糖尿病致肝损伤机制的研究进展[J]. 肝脏, 2023, 28(6): 737-739. |
| [9] | 黄孙桦, 刘建东, 黄罡. 肝细胞癌免疫治疗生物标志物的研究进展[J]. 肝脏, 2023, 28(5): 510-512. |
| [10] | 陈克敏. 成像生物标记物预测肝细胞癌免疫治疗反应的研究进展[J]. 肝脏, 2023, 28(5): 513-514. |
| [11] | 赵喜君, 杨宁. 肿瘤异质性在原发性肝癌中的研究进展[J]. 肝脏, 2023, 28(5): 515-517. |
| [12] | 丁忠丽, 崔蕾, 储开东. CAR和CD4+/CD8+与传染性单核细胞增多症合并肝损伤患儿病情及其预后的相关性[J]. 肝脏, 2023, 28(5): 593-598. |
| [13] | 贾刚刚, 卢利霞, 李斌, 林通, 王曈辉, 王秀锋, 马俊, 何毅刚, 于晓辉. 微生物群靶向治疗在非酒精性脂肪性肝病中的临床研究进展[J]. 肝脏, 2023, 28(5): 621-624. |
| [14] | 范芯铷, 刘铭佳, 王庆, 汪慧. 原发性肝癌的发病机制及治疗进展[J]. 肝脏, 2023, 28(4): 391-392. |
| [15] | 王资隆, 饶慧瑛. PPARα激动剂治疗非酒精性脂肪性肝病的研究进展[J]. 肝脏, 2023, 28(4): 396-397. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
